Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
massimo.breccia@uniroma1.it
Massimo Breccia
Professore Associato
Struttura:
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
E-mail:
massimo.breccia@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
THE NEW ENGLAND JOURNAL OF MEDICINE
2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
HAEMATOLOGICA
2019
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
BLOOD ADVANCES
2019
Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data
ACTA HAEMATOLOGICA
2019
A journey through infectious risk associated with ruxolitinib
BRITISH JOURNAL OF HAEMATOLOGY
2019
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
LEUKEMIA RESEARCH
2019
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
ANNALS OF HEMATOLOGY
2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
ANNALS OF HEMATOLOGY
2019
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
JOURNAL OF HEMATOLOGY & ONCOLOGY
2019
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
SEMINARS IN ONCOLOGY
2019
Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome
HEMATOLOGICAL ONCOLOGY
2019
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
CURRENT ONCOLOGY REPORTS
2018
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia
ANNALS OF HEMATOLOGY
2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
ONCOTARGET
2018
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes
LEUKEMIA RESEARCH
2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
ANNALS OF HEMATOLOGY
2018
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option
CLINICAL DRUG INVESTIGATION
2018
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy
EXPERT REVIEW OF HEMATOLOGY
2018
Association between proteomic profile and molecular response in chronic myeloid leukemia patients
LEUKEMIA & LYMPHOMA
2018
« prima
< precedente
…
9
10
11
12
13
14
15
16
17
18
19
20
…
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma